Quiz 3: RNA-based therapy

What is one key difference in the nature of action

between small-molecule drugs and siRNA-based drugs?

• Small molecules are highly specific and potent, unlike siRNA-based drugs.

• Small molecules predominantly target extracellular sites, unlike siRNA-based drugs.

• Small molecules only activate targets, while siRNA-based drugs only inhibit targets.

• Small molecules can activate or inhibit targets, whereas siRNA-based drugs predominantly inhibit targets.

What is the primary mechanism of action for

antisense oligonucleotide (ASO)-based RNA drugs in human cells?

• Inhibition of DNA replication

• Enhancement of mRNA splicing

• Induction of RNase H-mediated degradation of target mRNA

• Blocking the translation of miRNA

Which of the following RNA-based therapeutics is described

in the text, as having no known application in protein synthesis?

• Aptamer

• mRNA

• Antisense oligonucleotide (ASO)

• Small interfering RNAs (siRNAs)

Which of the following properties is associated

with RNA-based therapeutics, as stated in the text?

• RNA-based drugs act by activating targets.

• RNA-based drugs are stable and easy to manufacture.

• RNA-based drugs have potential immunogenicity issues.

• RNA-based drugs require complex synthesis in living cells.

What is the role of AGO2 in the RNA-induced silencing complex (RISC) during the siRNA mechanism?

• It cleaves the target mRNA directly.

• It cleaves the passenger strand of siRNA.

• It processes dsRNA into siRNA.

• It guides the siRNA to the target mRNA.

What makes the design of RNA therapeutics easier

compared to other types of drugs (such as antibody)?

• RNA drugs target a smaller portion of the human genome.

• The defined sequence of RNA drugs.

• RNA drugs are easily delivered to intracellular sites.

• RNA drugs do not cause off-target effects.

What is one of the main focuses for the next generation of RNA-based therapeutics?

• Increase the complexity of RNA structures.

• Develop more immunogenic RNA molecules.

• Optimize potent and specific delivery to target.

• Synthesize RNA using only living cells.

Which therapeutic approach is associated with RNA aptamers according to the text?

• RNA interference-mediated cleavage of mRNA

• Gene editing through CRISPR technology

• Antagonistic binding to VEGF protein

• Activation of immune cells for targeted therapy

What type of molecule is an aptamer?

• Oligonucleotide

• Lipid

• RNA-protein complex

• Protein

Which topic is not presented as a group today?

• Aptamer

• Small interfering RNAs (siRNAs)

• Antisense oligonucleotide

  (ASO)

• miRNA